News
-
-
PRESS RELEASE
Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Heidelberg Pharma AG reports financial figures, business performance in 2025, and outlook for 2026, including CEO appointment, cost-cutting program, and extended cash runway. Fast Track designation for HDP-101 by FDA -
-
PRESS RELEASE
Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
Heidelberg Pharma to receive milestone payment from partner Huadong for clinical study with HDP-101 in China. First patient dosed in Phase I study evaluating safety, tolerability, and efficacy -
-
PRESS RELEASE
Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and participation of Soleus Capital, securing financing until mid-2027. USD 20 million upfront from Soleus Capital and USD 25 million upon FDA approval of TLX250-Px -
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and partnership with Soleus Capital, securing upfront and milestone payments -
-
